NRXS — Neuraxis, Inc.
AMEX · Healthcare · Biotechnology
$5.98
+$0.17 (+2.93%)
Neuraxis, Inc. (NRXS) is a biotechnology company listed on AMEX. It is led by Brian Carrico, based in 11611 North Meridian St, Carmel, IN, United States, 46032, with about 24 employees. NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Latest reported NRXS revenue for 2025-09-30 was $811.4K. Net income was -$2.1M. Revenue was down 9.2% from 2025-06-30 to 2025-09-30. NRXS currently screens at market cap $83.1M.
Use this NRXS page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the NRXS quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the NRXS SEC filings page. Lician reads the product cache first so this HTML stays unique to Neuraxis, Inc. even when a live quote feed is slow.
About Neuraxis, Inc.
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8 years of age with functional abdominal pain associated with irritable bowel syndrome (IBS), functional dyspepsia (FD) and associated FD nausea symptoms. The company also offers rectal expulsion device, a screening tool that helps to detects evacuation disorders. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
NRXS Key Statistics
Market Cap
$83.10M
Volume
64,478
Previous Close
$6.04
Day Range
$5.98 – $6.20
P/B Ratio
14.47
EPS
-$1.22
Revenue
$2.69M
Net Income
-$8.24M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+9.2%
Profit Margin
-306.8%
Employees
24
NRXS Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 |
|---|---|---|---|
| Revenue | $2.69M | $2.46M | $2.68M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.24M | -$14.63M | -$4.78M |
| EPS (Diluted) | -$1.22 | -$4.50 | -$2.77 |
Total Assets
$4.76M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$3.70M
Operating Cash Flow
-$6.10M
Free Cash Flow
$0.00
Neuraxis, Inc. Company Information
- President, CEO & Director
- Brian Carrico
- Headquarters
- 11611 North Meridian St, Carmel, IN, United States, 46032
- Website
- neuraxis.com
- Phone
- 812 689 0791
- IPO / Founded
- 2023-08-09
- Sector
- Healthcare
- Industry
- Biotechnology